Advertisement
Home Tags Cancer: Kidney

Tag: Cancer: Kidney

Patients Favor Single-Port Robotic System for Uro-Oncology Surgery

0

Patients in the single-port versus multiport system group reported better cosmetic appearance, higher satisfaction with cosmetic appearance of surgical scar

Triplet Therapy Ups Progression-Free Survival in Advanced Kidney Cancer

0

PFS improved with cabozantinib + nivolumab + ipilimumab for patients with previously untreated advanced renal cell carcinoma

Adjuvant Nivolumab + Ipilimumab Lacks Efficacy for Localized RCC

0

Trial did not meet primary efficacy end point of disease-free survival in patients with localized RCC at high risk for postnephrectomy relapse

Treatments Compared for Advanced Renal Cell Carcinoma

0

Treatment-free survival more than twice as long for nivolumab plus ipilimumab versus sunitinib for intermediate/poor-risk patients

Adjuvant Pembrolizumab Beneficial in Renal Cell Carcinoma

0

Rate of disease-free survival at 24 months higher with pembrolizumab versus placebo following nephrectomy

Occult Brain Mets Detected in Patients With Advanced Renal Cancer

0

Asymptomatic brain metastases incidentally diagnosed in about 4 percent of patients with mRCC during clinical trial screening

Nivolumab Plus Cabozantinib Tops Sunitinib for Renal Cell Carcinoma

0

Combination therapy superior with respect to progression-free, overall survival and overall response for first-line treatment of advanced RCC

Lenvatinib Plus Pembrolizumab Tops Sunitinib in Advanced RCC

0

Progression-free, overall survival significantly longer with combo versus sunitinib for advanced renal cell carcinoma

Cabozantinib Prolongs PFS in Papillary Renal Cell Carcinoma

0

Progression-free survival longer and response rate greater for cabozantinib versus sunitinib in phase 2 trial in adults with PRCC

Nivolumab combined with cabozantinib is superior to sunitinib alone for the treatment of advanced clear cell renal cell carcinoma

Immunotherapy Combo Treats Advanced Kidney Cancer

0
First results show survival benefit with nivolumab plus cabozantinib versus sunitinib